0 15 Transactivation Transactivation NNP 16 18 by by IN 19 24 CIITA CIITA NNP 24 25 , , , 26 29 the the DT 30 34 type type NN 35 37 II ii CD 38 42 bare bare JJ 43 53 lymphocyte lymphocyte NN 54 73 syndrome-associated syndrome-associated JJ 74 80 factor factor NN 80 81 , , , 82 90 requires require VBZ 91 104 participation participation NN 105 107 of of IN 108 116 multiple multiple JJ 117 124 regions region NNS 125 127 of of IN 128 131 the the DT 132 136 TATA TATA NNP 137 140 box box NN 141 148 binding binding NN 149 156 protein protein NN 156 157 . . . 159 164 CIITA CIITA NNP 165 167 is be VBZ 168 169 a a DT 170 178 positive positive JJ 179 188 regulator regulator NN 189 191 of of IN 192 197 class class NN 198 200 II ii CD 201 206 major major JJ 207 225 histocompatibility histocompatibility NN 226 233 complex complex NN 234 238 gene gene NN 239 252 transcription transcription NN 253 257 that that WDT 258 261 has have VBZ 262 266 been be VBN 267 272 found find VBN 273 275 to to TO 276 278 be be VB 279 288 defective defective JJ 289 291 in in IN 292 295 one one CD 296 298 of of IN 299 302 the the DT 303 307 five five CD 308 323 complementation complementation NN 324 330 groups group NNS 331 333 of of IN 334 339 class class NN 340 342 II ii CD 343 348 major major JJ 349 367 histocompatibility histocompatibility NN 368 384 complex-negative complex-negative JJ 385 389 cell cell NN 390 395 lines line NNS 395 396 . . . 397 400 Its its PRP$ 401 411 N-terminal n-terminal JJ 412 418 region region NN 419 421 is be VBZ 422 429 capable capable JJ 430 432 of of IN 433 443 activating activate VBG 444 457 transcription transcription NN 458 462 from from IN 463 464 a a DT 465 473 reporter reporter NN 474 478 gene gene NN 479 483 when when WRB 484 489 fused fuse VBN 490 492 to to TO 493 494 a a DT 495 498 DNA dna NN 499 506 binding binding NN 507 513 domain domain NN 513 514 . . . 515 517 We we PRP 518 522 have have VBP 523 535 investigated investigate VBN 536 539 the the DT 540 549 mechanism mechanism NN 550 552 of of IN 553 568 transactivation transactivation NN 569 577 mediated mediate VBN 578 580 by by IN 581 584 the the DT 585 590 CIITA CIITA NNP 591 601 activation activation NN 602 608 domain domain NN 609 611 by by IN 612 620 studying study VBG 621 624 its its PRP$ 625 629 role role NN 630 632 in in IN 633 636 the the DT 637 644 process process NN 645 647 of of IN 648 661 transcription transcription NN 662 672 initiation initiation NN 673 676 and and CC 677 687 elongation elongation NN 687 688 . . . 689 701 Specifically specifically RB 702 705 the the DT 706 713 altered altered JJ 714 725 specificity specificity NN 726 729 TBP TBP NNP 730 731 ( ( ( 731 735 TATA TATA NNP 736 739 box box NN 740 747 binding binding NN 748 755 protein protein NN 755 756 ) ) ) 757 762 assay assay NN 763 766 has have VBZ 767 771 been be VBN 772 776 used use VBN 777 779 to to TO 780 787 analyze analyze VB 788 791 the the DT 792 800 response response NN 801 803 of of IN 804 807 the the DT 808 813 CIITA CIITA NNP 814 824 activation activation NN 825 831 domain domain NN 832 834 to to TO 835 844 mutations mutation NNS 845 847 in in IN 848 851 TBP TBP NNP 852 857 known know VBN 858 860 to to TO 861 868 disrupt disrupt VB 869 872 its its PRP$ 873 884 interaction interaction NN 885 889 with with IN 890 893 its its PRP$ 894 904 associated associate VBN 905 912 general general JJ 913 920 factors factor NNS 920 921 . . . 922 937 Transactivation Transactivation NNP 938 940 by by IN 941 946 CIITA CIITA NNP 947 950 was be VBD 951 960 extremely extremely RB 961 970 sensitive sensitive JJ 971 973 to to TO 974 975 a a DT 976 984 mutation mutation NN 985 987 in in IN 988 991 TBP TBP NNP 992 996 that that IN 997 999 in in IN 1000 1005 yeast yeast NN 1006 1008 is be VBZ 1009 1014 known know VBN 1015 1017 to to TO 1018 1025 abolish abolish VB 1026 1039 VP16-mediated vp16-mediated JJ 1040 1053 transcription transcription NN 1054 1057 but but CC 1058 1064 leaves leave VBZ 1065 1070 basal basal JJ 1071 1084 transcription transcription NN 1085 1095 unaffected unaffected JJ 1095 1096 . . . 1097 1098 A a DT 1099 1102 TBP TBP NNP 1103 1109 mutant mutant NN 1110 1119 defective defective JJ 1120 1122 in in IN 1123 1134 interaction interaction NN 1135 1139 with with IN 1140 1154 TBP-associated tbp-associated JJ 1155 1161 factor factor NN 1162 1170 TAFII250 tafii250 NN 1171 1175 also also RB 1176 1182 failed fail VBD 1183 1185 to to TO 1186 1193 mediate mediate VB 1194 1209 transactivation transactivation NN 1210 1217 through through IN 1218 1221 the the DT 1222 1227 CIITA CIITA NNP 1228 1238 activation activation NN 1239 1245 domain domain NN 1245 1246 . . . 1247 1254 Certain certain JJ 1255 1267 interactions interaction NNS 1268 1275 between between IN 1276 1279 TBP TBP NNP 1280 1283 and and CC 1284 1291 general general JJ 1292 1299 factors factor NNS 1300 1304 that that WDT 1305 1308 are be VBP 1309 1321 specifically specifically RB 1322 1330 required require VBN 1331 1334 for for IN 1335 1341 acidic acidic JJ 1342 1352 activation activation NN 1353 1360 domains domain NNS 1361 1365 were be VBD 1366 1370 also also RB 1371 1379 required require VBN 1380 1383 for for IN 1384 1398 CIITA-mediated ciita-mediated JJ 1399 1414 transactivation transactivation NN 1415 1417 to to TO 1418 1423 reach reach VB 1424 1427 its its PRP$ 1428 1432 full full JJ 1433 1442 potential potential NN 1442 1443 . . . 1444 1451 Finally finally RB 1451 1452 , , , 1453 1457 like like IN 1458 1462 VP16 VP16 NNP 1462 1463 , , , 1464 1469 CIITA CIITA NNP 1470 1473 was be VBD 1474 1478 able able JJ 1479 1481 to to TO 1482 1491 stimulate stimulate VB 1492 1502 elongation elongation NN 1503 1505 of of IN 1506 1519 transcription transcription NN 1519 1520 . . . 1521 1528 Overall overall RB 1529 1532 the the DT 1533 1542 mechanism mechanism NN 1543 1545 of of IN 1546 1561 transactivation transactivation NN 1562 1564 by by IN 1565 1568 the the DT 1569 1574 human human JJ 1575 1590 B-cell-specific b-cell-specific JJ 1591 1596 CIITA CIITA NNP 1597 1599 is be VBZ 1600 1604 very very RB 1605 1612 similar similar JJ 1613 1615 to to TO 1616 1620 that that DT 1621 1629 mediated mediate VBN 1630 1632 by by IN 1633 1636 the the DT 1637 1643 herpes herpes NN 1644 1649 virus virus NN 1650 1664 transactivator transactivator NN 1665 1669 VP16 vp16 NN 1670 1672 in in IN 1673 1676 the the DT 1677 1681 ways way NNS 1682 1686 that that WDT 1687 1691 have have VBP 1692 1696 been be VBN 1697 1703 tested test VBN 1703 1704 . . .